Davis, JM, Matalon, L, Watanabe, MD, Blake, L. Depot antipsychotic drugs. Place in therapy. Drugs
1994; 47: 741–73.
Patel, MX, David, AS. Why aren't depot antipsychotics prescribed more often, and what can be done about it?
Advan Psychiatr Treat
2005; 11: 203–13.
Johnson, DAW. Historical perspective on antipsychotic long-acting injections. Br J Psychiatry
2009; 195 (suppl 52): s7–12.
Haddad, PM, Taylor, M, Niaz, OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trial and observational studies. Br J Psychiatry
2009; 195 (suppl 52): s20–8.
Robinson, D, Woerner, MG, Alvir, JMJ, Bilder, R, Goldman, R, Geisler, S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry
1999; 56: 241–7.
Barnes, TRE, Shingleton-Smith, A, Paton, C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry
2009; 195 (suppl 52): s37–42.
Miles, CP. Conditions predisposing to suicide: a review. J Nerv Ment Dis
1977; 164: 231–46.
Palmer, BA, Pankratz, VS, Bostwick, JM. The lifetime risk of suicide in schizophrenia. Arch Gen Psychiatry
2005; 62: 247–53.
Fleischhacker, WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry
2009; 195 (suppl 52): s29–36.
Dencker, SJ, Axelsson, R. Optimising the use of depot antipsychotics. CNS Drugs
1996; 6: 367–81.
Johnson, DAW, Wright, NF. Drug prescribing for schizophrenic out-patients on depot injections: repeat surveys over 18 years. Br J Psychiatry
1990; 156: 827–34.
Shah, AK. Prescribing patterns in a psychiatric follow-up clinic. Psychiatr Bull
1991; 15: 484–5.
Galletly, CA. Antipsychotic drug doses in a schizophrenia inpatient unit. Aust N Z J Psychiatry
1992; 26: 574–6.
Barnes, TRE, Curson, DA. Long-acting depot antipsychotics: a risk–benefit assessment. Drug Saf
1994; 10: 464–79.
Callaly, T, Trauer, T. Patterns of use of antipsychotic medication in a regional community mental health service. Australas Psychiatry
2000; 8: 220–4.
Cramer, JA, Rosenheck, R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv
1998; 49: 196–201.
Pinikahana, J, Happell, B, Taylor, M, Keks, NA. Exploring the complexity of compliance in schizophrenia. Issues Ment Health Nurs
2002; 23: 5123–8.
Zygmunt, A, Olfson, M, Boyer, CA, Mechanic, D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry
2002; 159: 1653–64.
Valenstein, M, Ganoczy, D, McCarthy, JF, Myra Kim, H, Lee, TA, Blow, FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia. A retrospective review. J Clin Psychiatry
2006; 67: 1542–50.
Wistedt, B. How does the psychiatric patient feel about depot treatment, compulsion or help?
Nord J Psychiatry
1995; 49 (suppl 35): 41–6.
Levine, J, Schooler, NR, Cassano, GB. The role of depot neuroleptics in the treatment of schizophrenic patients. Psychol Med
1979; 9: 383–6.
Young, JL, Zonana, HV, Shepler, L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law
1986; 14: 105–22.
Young, JL, Spitz, RT, Hillbrand, M, Danieri, G. Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments and prospects. J Am Acad Psychiatry Law
1999; 27: 426–44.
Heyscue, BE, Levin, GM, Merrick, JP. Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv
1998; 49: 1232–4.
Tattan, TMG, Creed, FH. Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull
2001; 27: 149–55.
Shi, L, Ascher-Svanum, H, Zhu, B, Faries, D, Montgomery, W, Marder, SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Serv
2007; 58: 482–8.
Paton, C, Barnes, TRE, Cavanagh, MR, Taylor, D, Lelliott P, the POMH–UK project team. High-dose and combination antipsychotic prescribing in acute adult wards in the UK; the challenges posed by p.r.n. prescribing. Br J Psychiatry
2008; 192: 435–9.
Barnes, TRE, Paton, C, Cavanagh, MR, Hancock, E, Taylor, DM. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull
2007; 33: 1397–401.
Barnes, TRE, Paton, C, Hancock, E, Cavanagh, MR, Taylor, D, Lelliott, P. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand
2008; 118: 26–33.
Waddell, L, Taylor, M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry
2009; 195 (suppl 52): s43–50.
Gray, R, Spilling, R, Burgess, D, Newey, T. Antipsychotic long-acting injections in clinical practice: medication management and patient choice. Br J Psychiatry
2009; 195 (suppl 52): s51–6.
Kane, JM, Aguglia, E, Altamura, AC, Ayuso Gutierrez, JL, Brunello, N, Fleischhacker, WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol
1998; 8: 55–66.
Patel, MX, Nikolaou, V, David, AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med
2003; 33: 83–9.
Glazer, WM. The depot paradox. Behav Healthcare
2007; 27: 44–6.
Adams, CE, Fenton, MKP, Quraishi, S, David, AS. Systemic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry
2001; 179: 290–9.
Lieberman, JA, Stroup, S, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.
Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IPW, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet
2008; 371: 1085–97.
Taylor, D. Psychopharmacology and adverse effects of antipsychotic long-acting injections. Br J Psychiatry
2009; 195 (suppl 52): s13–9.
Correll, CU, Rummel-Kluge, C, Corves, C, Kane, JM, Leucht, S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomised controlled trials. Schizophr Bull
2009; 35: 443–57.
Voruganti, L, Cortese, L, Oyewumi, L, Cernovsky, Z, Awad, A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res
2000; 43: 135–45.
Davis, JM, Chen, N, Glick, ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry
2003; 60: 553–64.
Heres, S, Hamann, J, Kissling, W, Leucht, S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry
2006; 67: 1948–53.
Kane, JM, Garcia-Ribera, C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry
2009; 195 (suppl 52): s63–7.
Lambert, TJ, Singh, BS, Patel, MX. Community treatment orders and antipsychotic long-acting injections. Br J Psychiatry
2009; 195 (suppl 52): s57–62.